Diagnostic accuracy of pleural fluid to serum carcinoembryonic antigen ratio and delta value for malignant pleural effusion: findings from two cohorts. 2023

Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Pleural fluid (PF) carcinoembryonic antigen (CEA) is a widely used diagnostic marker for malignant pleural effusion (MPE). Recent studies revealed that PF to serum CEA was also a promising diagnostic parameter for MPE. We aimed to investigate whether PF to serum CEA ratio and delta CEA (PF minus serum CEA) provided added value to PF CEA in diagnosing MPE. Patients with pleural effusion in a retrospective cohort (BUFF) and a prospective cohort (SIMPLE) were included. The clinical characteristics of the patients were extracted from their medical records. The diagnostic value of CEA ratio and delta CEA was estimated by a receiver operating characteristics (ROC) curve, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). A total of 148 patients in the BUFF cohort and 164 patients in the SIMPLE cohort were enrolled. The BUFF cohort had 46 MPE patients and 102 benign pleural effusion (BPE) patients, and the SIMPLE cohort had 85 MPE patients and 79 BPE patients. In both cohorts, MPE patients had significantly higher PF CEA, serum CEA, CEA ratio, and delta CEA. The area under ROC curves (AUCs) of PF CEA, CEA ratio, and delta CEA were 0.78 (95% CI: 0.67-0.88), 0.80 (95% CI: 0.72-0.89) and 0.83 (95% CI: 0.75-0.91) in the BUFF cohort, and 0.89 (95% CI: 0.83-0.94), 0.86 (95% CI: 0.80-0.92), and 0.84 (95% CI: 0.78-0.91) in the SIMPLE cohort. The differences between the AUCs of PF CEA, CEA ratio, and delta CEA did not reach statistical significance. The continuous NRI and IDI of CEA ratio and delta CEA were <0. CEA ratio and delta value cannot provide added diagnostic value to PF CEA. The simultaneous determination of serum and PF CEA should not be adopted in clinical practice.

UI MeSH Term Description Entries
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016066 Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells. Malignant Pleural Effusion,Effusion, Malignant Pleural,Effusions, Malignant Pleural,Malignant Pleural Effusions,Pleural Effusions, Malignant

Related Publications

Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
January 2019, Therapeutic advances in medical oncology,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
January 1988, Vojnosanitetski pregled,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
January 2000, Respiration; international review of thoracic diseases,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
June 2008, Respirology (Carlton, Vic.),
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
March 1984, Nihon Kyobu Shikkan Gakkai zasshi,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
March 2018, The clinical respiratory journal,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
September 2017, Journal of clinical laboratory analysis,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
October 2020, Anticancer research,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
January 2024, Therapeutic advances in respiratory disease,
Meng-Ping Jiang, and Jian-Xun Wen, and Ling Hai, and Ting-Wang Jiang, and Jin-Hong Huang, and Hong Chen, and Ya-Fei Wang, and Wen-Qi Zheng, and Zhi-De Hu, and Li Yan
October 2010, Medicina clinica,
Copied contents to your clipboard!